International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study
| العنوان: | International Normalized Ratio as a Screening Test for Assessment of Anticoagulant Activity for Patients Treated With Rivaroxaban or Apixaban: A Pilot Study |
|---|---|
| المؤلفون: | Matitiahu Berkovitch, Maya Berlin, Dana Barchel, Ahmad Mahajna, Fanny Ofek, Tomer Ziv-Baran, Talia Filipovich-Rimon, Osnat Garach-Jehoshua, Nofar Perets |
| المصدر: | Frontiers in Pharmacology, Vol 10 (2019) Frontiers in Pharmacology |
| بيانات النشر: | Frontiers Media S.A., 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, INR, medicine.medical_specialty, Screening test, Hospitalized patients, apixaban, Anticoagulant activity, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Pharmacology (medical), Patient group, rivaroxaban, Original Research, Pharmacology, Prothrombin time, Rivaroxaban, medicine.diagnostic_test, business.industry, anti-FXa activity, lcsh:RM1-950, direct oral anti- FXa anticoagulants, 030104 developmental biology, lcsh:Therapeutics. Pharmacology, anti-FXa chromogenic assay, 030220 oncology & carcinogenesis, Activated factor X, Apixaban, business, medicine.drug |
| الوصف: | Introduction: In patients treated with direct oral anti activated factor X (anti-FXa) anticoagulants such as apixaban and rivaroxaban, there are several emergency and non-emergency conditions in which anticoagulation activity should be measured. The validity of the common global clotting tests, prothrombin time and international normalized ratio (PT/INR) for determination of blood levels of these drugs, has been widely investigated. As the anticoagulation activity evaluation “calibrated anti-FXa” of these drugs is relatively more expensive and less available, we aimed to build a prediction model for anticoagulation activity assessment based on INR values.Methods and Findings: One hundred sixty samples from 80 hospitalized patients treated with apixaban or rivaroxaban were tested using PT/INR and Anti-FXa chromogenic assay. Two blood samples, trough and peak, were collected from each subject. Participants were randomly divided into two equal groups. One group (n = 40) was used to build the model, which was validated by the second group (n = 40). There was a strong correlation between anti-FXa concentrations and INR in rivaroxaban treated patients (r = 0.899, p < 0.001). Therefore, we were able to build a formula for rivaroxaban patient group which reliably represent the relationship between these two parameters. The correlation in apixaban treated patients was less predictive (r = 0.798, p < 0.001) and the formula suggested could not be validated.Conclusions: In our study, we developed a formula that estimates the anticoagulant activity of rivaroxaban by obtaining INR values. Where anti-FXa assay is unavailable, our proposed formula may be considered as a screening test for rivaroxaban. |
| اللغة: | English |
| تدمد: | 1663-9812 |
| DOI: | 10.3389/fphar.2019.01177/full |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2da08531298b86fa1eff6749900c323 https://www.frontiersin.org/article/10.3389/fphar.2019.01177/full |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b2da08531298b86fa1eff6749900c323 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16639812 |
|---|---|
| DOI: | 10.3389/fphar.2019.01177/full |